stockrow
Saturday 7 November 2026
Export CERO’s income statement to Excel — free account
CERo Therapeutics Holdings, Inc.
CERO Healthcare Biotechnology
- EPS
- +98.9%
- Free cash flow
- +49.7%
Quarter to June 2026, against a year earlier
0.00
0.00
NaN
Follow CERO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | 0 | 0 | (7) | (8) | (20) | (16) | +178.2% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | — | 0 | (1) | (7) | (8) | (20) | (16) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | (136.97) | (290.56) | (24,972.86) | — | (22.58) | (13.23) | (36.3%) | ||||||
| Cash flow | — | — | — | — | — | (303.09) | (474.87) | (19,835.56) | (445.38) | (3.80) | (0.29) | (66.5%) | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | (303.09) | (474.87) | (19,835.56) | (445.38) | (3.68) | (0.29) | (66.8%) | ||||||
| Book value | — | — | — | — | — | (3,334.74) | (4,782.70) | (144,082.56) | (65.33) | (1.29) | (0.72) | (86.0%) | ||||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 0 | 4 | 19 | +554.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (1) | (6) | (13) | (16) | (12) | +119.2% | |||||
| Capex | — | — | — | — | — | — | — | — | — | 1 | — | — | ||||||
| Free cash flow | — | — | — | — | — | (1) | (1) | (6) | (13) | (16) | (12) | +117.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | 12 | (2) | (4) | (6) | (31) | n/m | |||||
| Net debt | — | — | — | — | — | (1) | 0 | (2) | (3) | (2) | 0 | +10.9% | ||||||
| Shareholders’ equity | — | — | — | — | — | (8) | (11) | (42) | (2) | (5) | (31) | (8.2%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (0.18) | (0.60) | (30.70) | (195.70) | (1,940.02) | (2,352.32) | (1,939.8) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | (0.39) | 7.15 | 27.48 | 47.06 | 1,074.49 | 453.76 | +1,074.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 3 | 9 | 8 | 8 | — | +27.8% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
CERo Therapeutics Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SPRC SciSparc Ltd. | $880.0K | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| LNAI Lunai Bioworks Inc. | $830.0K | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | Compare |
| ATXI Avenue Therapeutics, Inc. | $680.0K | — (loss-making) | — (loss-making) | — | n/m | −169.89% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MLEC Moolec Science SA | $620.0K | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | Compare |
| CDT CDT Equity Inc. | $390.0K | — (loss-making) | — | — | n/m | +78.92% (above 0%: growing) | — | 0.00% | Compare |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR | $320.0K | 0.0× | — (loss-making) | — | −85.80% (below 0%: shrinking) | +51.13% (above 0%: growing) | (228.63%) | (504.50%) | Compare |
| VINC Vincerx Pharma, Inc. | $250.0K | — (loss-making) | — | — | n/m | +42.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VRPX Virpax Pharmaceuticals, Inc. | $160.0K | — (loss-making) | — | — | n/m | +4.68% (above 0%: growing) | — | 0.00% | Compare |
| CERO CERo Therapeutics Holdings, Inc. | $140.0K | — (loss-making) | — | — | n/m | +49.65% (above 0%: growing) | — | 0.00% | |
| Median of peers | $505.0K | — | — | — | — | +9.82% | 17.88% | 0.00% |